Skip to main content
SpringerLink
Log in

Immune Status and Mesothelioma

  • Chapter
Malignant Mesothelioma

  • 932 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Musti M, Cavone D, Aalto Y, Scattone A, Serio G, Knuutila S. A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. Cancer Genet Cytogenet 2002;138:73–76.

    Article  PubMed  CAS  Google Scholar 

  2. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Geneticsusceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357:444–445.

    Article  PubMed  CAS  Google Scholar 

  3. Robinson CF, Petersen M, Palu S. Mortality patterns among electrical workers employed in the U.S. construction industry, 1982–1987. Am J Ind Med 1999;36:630–637.

    Article  PubMed  CAS  Google Scholar 

  4. Sluis-Cremer GK, Liddell FD, Logan WP, Bezuidenhout BN. The mortality of amphibole miners in South Africa, 1946–80. Br J Ind Med 1992;49:566–575.

    PubMed  CAS  Google Scholar 

  5. Selikoff IJ, Seidman H. Asbestos-associated deaths among insulation workers in the United States and Canada, 1967–1987. Ann NY Acad Sci 1991;643:1–14.

    PubMed  CAS  Google Scholar 

  6. Gazdar AF, Butel JS, Carbone M. SV40 and human tumors: myth, association or causality? Nature Cancer Rev (in press).

    Google Scholar 

  7. Lowdell MW, Lamb L, Hoyle C, Velardi A, Prentice HG. Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. Br J Haematol 2001;114:11–24.

    Article  PubMed  CAS  Google Scholar 

  8. Mavaddat N, Robinson BW, Rose AH, Manning LS, Garlepp MJ. An analysis of the relationship between gd T cell receptor V gene usage and nonmajor histocompatibility complex-restricted cytotoxicity. Immunol Cell Biol 1993;71(part 1):27–37.

    PubMed  CAS  Google Scholar 

  9. Sussman JJ, Shu S, Sondak VK, Chang AE. Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol 1994;1:296–306.

    Article  PubMed  CAS  Google Scholar 

  10. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823–1841.

    Article  PubMed  CAS  Google Scholar 

  11. Basse PH, Whiteside TL, Herberman RB. Cancer immunotherapy with interleukin-2-activated natural killer cells. Mol Biotechnol 2002;21:161–170.

    Article  PubMed  CAS  Google Scholar 

  12. Lew F, Tsang P, Holland JF, Warner N, Selikoff IJ, Bekesi JG. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol 1986;6:225–233.

    Article  PubMed  CAS  Google Scholar 

  13. Lanier LL. NK cell receptors. Annu Rev Immunol 1998;16:359–393.

    Article  PubMed  CAS  Google Scholar 

  14. Christmas TI, Manning LS, Davis MR, Robinson BW, Garlepp MJ. HLA antigen expression and malignant mesothelioma. Am J Respir Cell Mol Biol 1991;5:213–220.

    PubMed  CAS  Google Scholar 

  15. Orengo AM, Spoletini L, Procopio A, et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 1999;13:527–534.

    Article  PubMed  CAS  Google Scholar 

  16. Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BW. Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma. Clin Immunol Immunopathol 1989;53:68–77.

    Article  PubMed  CAS  Google Scholar 

  17. Manning LS, Bowman RV, Darby SB, Robinson BW. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am Rev Respir Dis 1989;139:1369–1374.

    PubMed  CAS  Google Scholar 

  18. Kagan E, Solomon A, Cochrane JC, et al. Immunological studies of patients with asbestosis. I. Studies of cell-mediated immunity. Clin Exp Immunol 1977;28:261–267.

    PubMed  CAS  Google Scholar 

  19. Haslam PL, Lukoszek A, Merchant JA, Turner-Warwick M. Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma. Clin Exp Immunol 1978;31:178–188.

    PubMed  CAS  Google Scholar 

  20. Gaumer HR, Doll NJ, Kaimal J, Schuyler M, Salvaggio JE. Diminished suppressor cell function in patients with asbestosis. Clin Exp Immunol 1981;44:108–116.

    PubMed  CAS  Google Scholar 

  21. deShazo RD, Nordberg J, Baser Y, Bozelka B, Weill H, Salvaggio J. Analysis of depressed cell-mediated immunity in asbestos workers. J Allergy Clin Immunol 1983;71:418–424.

    Article  PubMed  CAS  Google Scholar 

  22. Lange A, Smolik R, Chmielarczyk W, Garncarek D, Gielgier Z. Cellular immunity in asbestosis. Arch Immunol Ther Exp (Warsz) 1978;26:899–903.

    CAS  Google Scholar 

  23. Pierce R, Turner-Warwick M. Skin tests with tuberculin (PPD) Candida albicans and Trichophyton spp. in cryptogenic fibrosing alveolitis and asbestos related lung disease. Clin Allergy 1980;10:229–237.

    Article  PubMed  CAS  Google Scholar 

  24. Lange A, Garncarek D, Tomeczko J, Ciechanowski G, Bisikiewicz R. Outcome of asbestos exposure (lung fibrosis and antinuclear antibodies) with respect to skin reactivity: an 8-year longitudinal study. Environ Res 1986;41:1–13.

    Article  PubMed  CAS  Google Scholar 

  25. Rola-Pleszczynski M, Lemaire I, Sirois P, Masse S, Begin R. Asbestos related changes in pulmonary and systemic immune responses—early enhancement followed by inhibition. Clin Exp Immunol 1982;49:426–432.

    PubMed  CAS  Google Scholar 

  26. Kinugawa K, Ueki A, Yamaguchi M, et al. Activation of human CD4+CD45RA+ T cells by chrysotile asbestos in vitro. Cancer Lett 1992;66:99–106.

    Article  PubMed  CAS  Google Scholar 

  27. Yamashita N, Clement LT. Phenotypic characterization of the post-thymic differentiation of human alloantigen-specific CD8+ cytotoxic T lymphocytes. J Immunol 1989;143:1518–1523.

    PubMed  CAS  Google Scholar 

  28. Auerbach O, Conston AS, Garfinkel L, Parks VR, Kaslow HD, Hammond EC. Presence of asbestos bodies in organs other than the lung. Chest 1980;77:133–137.

    PubMed  CAS  Google Scholar 

  29. Dodson RF, Williams MG Jr, Corn CJ, Brollo A, Bianchi C. Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am Rev Respir Dis 1990;142:843–847.

    PubMed  CAS  Google Scholar 

  30. Roggli VL, Benning TL. Asbestos bodies in pulmonary hilar lymph nodes. Mod Pathol 1990;3:513–517.

    PubMed  CAS  Google Scholar 

  31. Kagan E, Solomon A, Cochrane JC, Kuba P, Rocks PH, Webster I. Immunological studies of patients with asbestosis. II. Studies of circulating lymphoid cell numbers and humoral immunity. Clin Exp Immunol 1977;28:268–275.

    PubMed  CAS  Google Scholar 

  32. Costabel U, Bross KJ, Huck E, Guzman J, Matthys H. Lung and blood lymphocyte subsets in asbestosis and in mixed dust pneumoconiosis. Chest 1987;91:110–112.

    PubMed  CAS  Google Scholar 

  33. Peng L, Wang X. Lymphocyte B and T cell subsets in peripheral blood from patients with asbestosis. Br J Ind Med 1993;50:183–184.

    PubMed  CAS  Google Scholar 

  34. Miller LG, Sparrow D, Ginns LC. Asbestos exposure correlates with alterations in circulating T cell subsets. Clin Exp Immunol 1983;51:110–116.

    PubMed  CAS  Google Scholar 

  35. Sprince NL, Oliver LC, McLoud TC, Eisen EA, Christiani DC, Ginns LC. Asbestos exposure and asbestos-related pleural and parenchymal disease. Associations with immune imbalance. Am Rev Respir Dis 1991;143:822–828.

    PubMed  CAS  Google Scholar 

  36. Wallace JM, Oishi JS, Barbers RG, Batra P, Aberle DR. Bronchoalveolar lavage cell and lymphocyte phenotype profiles in healthy asbestos-exposed shipyard workers. Am Rev Respir Dis 1989;139:33–38.

    PubMed  CAS  Google Scholar 

  37. Rom WN, Travis WD. Lymphocyte-macrophage alveolitis in nonsmoking individuals occupationally exposed to asbestos. Chest 1992;101:779–786.

    PubMed  CAS  Google Scholar 

  38. Robinson BW. Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2. Am Rev Respir Dis 1989;139:897–901.

    PubMed  CAS  Google Scholar 

  39. Manning LS, Davis MR, Robinson BW. Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma. Clin Exp Immunol 1991;83:85–91.

    Article  PubMed  CAS  Google Scholar 

  40. Yoneda T, Kitamura H, Narita N, Mikami R, Yokoyama K. NK cell activity in asbestosis. Eur J Respir Dis 1986;68:64–67.

    PubMed  CAS  Google Scholar 

  41. deShazo RD, Morgan J, Bozelka B, Chapman Y. Natural killer cell activity in asbestos workers. Interactive effects of smoking and asbestos exposure. Chest 1988;94:482–485.

    PubMed  CAS  Google Scholar 

  42. Froom P, Lahat N, Kristal-Boneh E, Cohen C, Lerman Y, Ribak J. Circulating natural killer cells in retired asbestos cement workers. J Occup Environ Med 2000;42:19–24.

    PubMed  CAS  Google Scholar 

  43. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982;61:1007–1009.

    PubMed  CAS  Google Scholar 

  44. Mudhar HS, Fisher PM, Wallace WA. No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura. Eur J Surg Oncol 2002;28:564–565.

    Article  PubMed  CAS  Google Scholar 

  45. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma—possible immunological mechanism. Lung Cancer 2001;32:197–201.

    Article  PubMed  CAS  Google Scholar 

  46. Robinson C, Robinson BW, Lake RA. Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 1998;20:175–184.

    Article  PubMed  CAS  Google Scholar 

  47. Robinson C, Callow M, Stevenson S, Scott B, Robinson BW, Lake RA. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol 2000;22:550–556.

    PubMed  CAS  Google Scholar 

  48. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002;29:5–11.

    Article  PubMed  CAS  Google Scholar 

  49. Ruiz-Cabello F, Cabrera T, Lopez-Nevot MA, Garrido F. Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol 2002;12:15–24.

    Article  PubMed  CAS  Google Scholar 

  50. Leong C, Marley J, Loh S, Robinson B, Garlepp M. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression. Cancer Gene Ther 1996;3:321–330.

    PubMed  CAS  Google Scholar 

  51. Leong CC, Marley JV, Loh S, Milech N, Robinson BW, Garlepp MJ. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int J Cancer 1997;71:476–482.

    Article  PubMed  CAS  Google Scholar 

  52. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999;59:1071–1079.

    PubMed  CAS  Google Scholar 

  53. Edwards JG, Faux SP, Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002;8:1857–1862.

    PubMed  CAS  Google Scholar 

  54. Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000;60:3696–3700.

    PubMed  CAS  Google Scholar 

  55. Velders MP, Macedo MF, Provenzano M, et al. Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of simian virus 40 large T antigen. J Cell Biochem 2001;82:155–162.

    Article  PubMed  CAS  Google Scholar 

  56. Bright RK, Kimchi ET, Shearer MH, Kennedy RC, Pass HI. SV40 Tagspecific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients. Cancer Immunol Immunother 2002;50:682–690.

    Article  PubMed  CAS  Google Scholar 

  57. Broaddus VC, Yang L, Scavo LM, Ernst JD, Boylan AM. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 1996;98:2050–2059.

    PubMed  CAS  Google Scholar 

  58. Mossman BT, Marsh JP, Sesko A, et al. Inhibition of lung injury, inflammation, and interstitial pulmonary fibrosis by polyethylene glycol-conjugated catalase in a rapid inhalation model of asbestosis. Am Rev Respir Dis 1990;141:1266–1271.

    PubMed  CAS  Google Scholar 

  59. Choe N, Tanaka S, Xia W, Hemenway DR, Roggli VL, Kagan E. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ Health Perspect 1997;105(suppl 5):1257–1260.

    PubMed  CAS  Google Scholar 

  60. Tanaka S, Choe N, Hemenway DR, Zhu S, Matalon S, Kagan E. Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat. J Clin Invest 1998;102:445–454.

    PubMed  CAS  Google Scholar 

  61. Iwagaki A, Choe N, Li Y, Hemenway DR, Kagan E. Asbestos inhalation induces tyrosine nitration associated with extracellular signal-regulated kinase 1/2 activation in the rat lung. Am J Respir Cell Mol Biol 2003;28:51–60.

    Article  PubMed  CAS  Google Scholar 

  62. Zhang P, Wang YZ, Kagan E, Bonner JC. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J Biol Chem 2000;275:22479–22486.

    Article  PubMed  CAS  Google Scholar 

  63. Reddy SP, Mossman BT. Role and regulation of activator protein-1 in toxicant-induced responses of the lung. Am J Physiol 2002;283:L1161–L1178.

    CAS  Google Scholar 

  64. Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002;62:6065–6069.

    PubMed  CAS  Google Scholar 

  65. Martins GA, Cardoso MA, Aliberti JC, Silva JS. Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice. Immunol Lett 1998;63:113–120.

    Article  PubMed  CAS  Google Scholar 

  66. Wu-Hsieh BA, Chen W, Lee HJ. Nitric oxide synthase expression in macrophages of Histoplasma capsulatum-infected mice is associated with splenocyte apoptosis and unresponsiveness. Infect Immun 1998;66:5520–5526.

    PubMed  CAS  Google Scholar 

  67. Mossalayi MD, Becherel PA, Debre P. Critical role of nitric oxide during the apoptosis of peripheral blood leukocytes from patients with AIDS. Mol Med 1999;5:812–819.

    PubMed  CAS  Google Scholar 

  68. Brito C, Naviliat M, Tiscornia AC, et al. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol 1999;162:3356–3366.

    PubMed  CAS  Google Scholar 

  69. Soini Y, Kahlos K, Puhakka A, et al. Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br J Cancer 2000;83:880–886.

    Article  PubMed  CAS  Google Scholar 

  70. Kojima M, Morisaki T, Tsukahara Y, et al. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J Surg Oncol 1999;70:222–229.

    Article  PubMed  CAS  Google Scholar 

  71. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor b signal transduction. J Leukoc Biol 2002;71:731–740.

    PubMed  CAS  Google Scholar 

  72. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001;186:153–168.

    Article  PubMed  CAS  Google Scholar 

  73. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFb-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543–552.

    Article  PubMed  CAS  Google Scholar 

  74. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350–353.

    PubMed  CAS  Google Scholar 

  75. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-b signaling in cancer. J Natl Cancer Inst 2000;92:1388–1402.

    Article  PubMed  Google Scholar 

  76. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Patho-and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994;39:347–359.

    Article  PubMed  CAS  Google Scholar 

  77. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BW. Transforming growth factor-b: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29–44.

    PubMed  CAS  Google Scholar 

  78. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor b2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997;57:3200–3207.

    PubMed  CAS  Google Scholar 

  79. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF b expression. J Pathol 1999;189:72–78.

    Article  PubMed  CAS  Google Scholar 

  80. Kuwahara M, Takeda M, Takeuchi Y, Harada T, Maita K. Transforming growth factor b production by spontaneous malignant mesothelioma cell lines derived from Fischer 344 rats. Virchows Arch 2001;438:492–497.

    Article  PubMed  CAS  Google Scholar 

  81. Maeda J, Ueki N, Ohkawa T, et al. Transforming growth factor-b 1 (TGF-b 1)-and b 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin Exp Immunol 1994;98:319–322.

    Article  PubMed  CAS  Google Scholar 

  82. Pasche B, Kolachana P, Nafa K, et al. TbR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999;59:5678–5682.

    PubMed  CAS  Google Scholar 

  83. Warshamana GS, Pociask DA, Sime P, Schwartz DA, Brody AR. Susceptibility to asbestos-induced and transforming growth factor-b1-induced fibroproliferative lung disease in two strains of mice. Am J Respir Cell Mol Biol 2002;27:705–713.

    PubMed  CAS  Google Scholar 

  84. Beck C, Schreiber H, Rowley D. Role of TGF-b in immune-evasion of cancer. Microsc Res Tech 2001;52:387–395.

    Article  PubMed  CAS  Google Scholar 

  85. Geller RL, Smyth MJ, Strobl SL, et al. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. J Immunol 1991;146:3280–3288.

    PubMed  CAS  Google Scholar 

  86. Yamanaka R, Tanaka R, Yoshida S, Saitoh T, Fujita K, Naganuma H. Suppression of TGF-b1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. J Neurooncol 1999;43:27–34.

    Article  PubMed  CAS  Google Scholar 

  87. Tamada K, Harada M, Abe K, et al. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes. J Immunol 1997;158:4846–4854.

    PubMed  CAS  Google Scholar 

  88. Takayama T, Kaneko K, Morelli AE, Li W, Tahara H, Thomson AW. Retroviral delivery of transforming growth factor-b1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation 2002;74:112–119.

    Article  PubMed  CAS  Google Scholar 

  89. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor b and reversal by recombinant tumor necrosis factor a. J Exp Med 1987;166:991–998.

    Article  PubMed  CAS  Google Scholar 

  90. Fontana A, Frei K, Bodmer S, et al. Transforming growth factor-b inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 1989;143:3230–3234.

    PubMed  CAS  Google Scholar 

  91. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-b signaling in T cells. Nat Med 2001;7:1118–1122.

    Article  PubMed  CAS  Google Scholar 

  92. Jagirdar J, Lee TC, Reibman J, et al. Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 1997;105(suppl 5):1197–1203.

    PubMed  Google Scholar 

  93. Perdue TD, Brody AR. Distribution of transforming growth factor-b1, fibronectin, and smooth muscle actin in asbestos-induced pulmonary fibrosis in rats. J Histochem Cytochem 1994;42:1061–1070.

    PubMed  CAS  Google Scholar 

  94. Bianchi C, Brollo A, Ramani L, Zuch C. Pleural plaques as risk indicators for malignant pleural mesothelioma: a necropsy-based study. Am J Ind Med 1997;32:445–449.

    Article  PubMed  CAS  Google Scholar 

  95. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-b1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768–776.

    Article  PubMed  CAS  Google Scholar 

  96. Baris YI, Sahin AA, Ozesmi M, et al. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 1978;33:181–192.

    Article  PubMed  CAS  Google Scholar 

  97. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002;29:82–96.

    Article  PubMed  CAS  Google Scholar 

  98. Astoul P, Viallat JR, Laurent JC, Brandely M, Boutin C. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993;103:209–213.

    PubMed  CAS  Google Scholar 

  99. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant g-interferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460–2467.

    Article  PubMed  CAS  Google Scholar 

  100. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 2001;31:303–310.

    Article  PubMed  CAS  Google Scholar 

  101. Davidson JA, Musk AW, Wood BR, et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother 1998;21:389–398.

    PubMed  CAS  Google Scholar 

  102. Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998;21:211–217.

    PubMed  CAS  Google Scholar 

  103. Monnet I, Breau JL, Moro D, et al. Intrapleural infusion of activated macrophages and g-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002;121:1921–1927.

    Article  PubMed  CAS  Google Scholar 

  104. Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000;7:1511–1518.

    Article  PubMed  CAS  Google Scholar 

  105. Albelda SM, Wiewrodt R, Sterman DH. Gene therapy for lung neoplasms. Clin Chest Med 2002;23:265–277.

    Article  PubMed  Google Scholar 

  106. Rizzo P, Bocchetta M, Powers A, et al. SV40 and the pathogenesis of mesothelioma. Semin Cancer Biol 2001;11:63–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

    Elliott Kagan MD, FRC Path

Authors
  1. Elliott Kagan MD, FRC Path
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Thoracic Oncology, Barbara Ann Karmanos Cancer Institute, Harper University Hospital, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  2. Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  3. Nevada Cancer Institute, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  4. Department of Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, 81935, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  5. Thoracic Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, 60153, USA

    Michele Carbone MD, PhD (Professor of Pathology, Director) (Professor of Pathology, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Kagan, E. (2005). Immune Status and Mesothelioma. In: Pass, H.I., Vogelzang, N.J., Carbone, M. (eds) Malignant Mesothelioma. Springer, New York, NY. https://doi.org/10.1007/0-387-28274-2_10

Download citation

  • DOI: https://doi.org/10.1007/0-387-28274-2_10

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-22949-2

  • Online ISBN: 978-0-387-28274-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation